Lifestyle modifications, including yoga, hypnosis, and nutraceuticals, are increasingly used in BPH management, reflecting a trend towards integrating alternative medicine with traditional treatments.

Olaparib significantly improved radiographic progression-free survival and overall survival in metastatic prostate cancer with HRR gene alterations. Safety profiles of PARP inhibitors were consistent ...

The TALAPRO-2 study authors noted that the use of androgen receptor (AR)–targeted therapy in clinical practice has increased considerably in recent years. How might prior use of AR-targeted therapy ...

The NRG-GU011 trial investigates relugolix plus SBRT versus SBRT alone in PET-oligometastatic prostate cancer. ORIOLE and STOMP studies indicate SBRT can delay recurrence without early ADT in some ...

The study is a large, multi-center, independently funded cohort series on Peyronie's disease treatment satisfaction. Patients who underpredict their penile curvature report higher satisfaction ...

Gallium PSMA-11 gozetotide is effective in detecting prostate cancer metastases and assessing biochemical recurrence with high sensitivity and specificity. The tracer is particularly useful for ...

PRP is popular for Peyronie disease due to its availability and safety, using patients' own biological factors. Limited data exist on PRP's efficacy for Peyronie disease, with studies showing no ...

Intravesical chemotherapy counseling differs for women due to potential skin irritation and leakage issues, necessitating specific skin care advice. Topical hormone therapy, such as vaginal estrogen ...

mCSPC and mHSPC refer to prostate cancer with metastases that remain responsive to hormone therapy, often used interchangeably. Both conditions involve the presence of metastases and sensitivity to ...

Prostate cancer significantly affects female partners' sexual quality of life, causing grief, isolation, and communication issues. The study aims to create a comprehensive questionnaire to assess ...

The revised policy will take effect on January 1, 2025. The Centers for Medicare & Medicaid Services (CMS) has announced an adjustment under the CY 2025 Hospital Outpatient Prospective Payment System ...

Casdatifan demonstrated a 34.4% objective response rate and 81.3% disease control rate in ccRCC patients, with no dose-limiting toxicities reported. The trial showed manageable safety, with anemia and ...